Chapter 22: Drugs for Muscle Spasm and Spasticity

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Imagine a patient comes into your clinic, right?

They have this excruciating lower back pain after a weekend of heavy lifting.

Oh, classic weekend warrior.

Exactly.

And you write a prescription for a standard muscle relaxer.

Yeah.

But what if I told you that medication isn't actually relaxing a single muscle fiber in their back?

Right.

It's a huge misconception.

It really is.

Okay.

So today on The Deep Dive, we are mastering Chapter 22 from Lane's Pharmacotherapeutics.

The chapter is Drugs for Muscle Spasm and Spasticity.

Yes, a very important one.

Consider this your dedicated one -on -one tutoring session.

We are mapping out the pathophysiology, the specific receptor mechanics, and those high stakes clinical decisions you have to make when you actually have the prescription pad in your hand.

The clinical reality of this chapter is that, well, these medications are ubiquitous in practice, but the potential for harm is just massive if you misunderstand the pharmacology.

If you prescribe based merely on the symptom of muscle tension rather than the underlying

pathophysiology, you really risk exacerbating functional deficits or triggering severe withdrawal syndrome.

Or missing those fatal drug interactions.

Exactly.

We have to trace the pharmacological logic directly to the patient -centered outcomes.

Okay.

So let's unpack this.

The absolute core pharmacotherapeutic rule of Chapter 22,

the dividing line we have to establish before looking at a single medication, is that not all muscle tension is created equal.

Right.

Not even close.

We have two entirely different groups of drugs because, well, we are treating two fundamentally different pathophysiological states, spasticity and localized muscle spasm.

And conflating the two is a major prescribing error.

I mean, spasticity is a movement disorder originating from upper motor neuron lesions.

So we're dealing with severe central nervous system damage.

Yes, exactly.

Conditions like multiple sclerosis, cerebral palsy, traumatic spinal cord lesions, or a stroke.

Because those descending inhibitory pathways from the brain are just obliterated, the spinal reflexes run unchecked.

Wow, okay.

Yeah, so the skeletal muscle itself is completely structurally sound, but the neurological signals commanding it are hyperactive.

And that leads to heightened tone, involuntary spasms, and, you know, a severe loss of dexterity.

But localized muscle spasm is a completely different clinical picture.

Like, the central nervous system in this patient is entirely intact.

Completely intact, yeah.

The involuntary contraction is driven by a localized mechanical or physiological insult,

acute trauma, sudden pain from a musculoskeletal injury, or even a metabolic imbalance like hypocalcemia.

Right.

The spinal pathways are totally fine there.

It's just the local tissue that is inflamed or irritated.

Which establishes our golden rule for prescribing.

Drugs intended for spasticity do not relieve acute localized muscle spasm.

And vice versa.

Drugs for acute muscle spasm are entirely ineffective against central spasticity.

They operate on completely different anatomical targets.

They are definitely not interchangeable, with one glaring exception, right?

Diazepam.

Right, diazepam.

It is the only medication in this entire class approved to bridge both worlds.

But outside of that, you really must identify your target.

You have to know what you're treating.

Exactly.

So since spasticity originates in the CNS, the logical therapeutic intervention is to target those hyperactive spinal pathways.

Which brings us to our first spasticity prototype.

Baclofen.

Yes, baclofen.

It is the foundational centrally acting agent for spasticity.

Its whole goal is to act directly within the spinal cord to suppress those uninhibited reflexes.

How it calms things down.

Exactly.

By decreasing flexor and extensor spasms, and suppressing resistance to passive movement, baclofen actually allows patients with MS or spinal cord injuries to regain a degree of functional performance.

The mechanism of action is pretty fascinating to me.

Baclofen is, well, it's essentially a structural twin of the inhibitory neurotransmitter GABA.

Yeah, it's a structural mimic.

Right.

It binds directly to GABA -B receptors in the spinal cord.

It basically operates like a neurological bouncer.

Just hyperpolarizing the presynaptic neurons and inhibiting the release of those excitatory neurotransmitters.

It quiets those hyperactive central signals, but it never actually crosses the neuromuscular junction to affect the skeletal muscle fibers directly.

Which is wild to think about.

And what about the pharmacokinetics?

Table 22 .2 highlights some details we need to anticipate, right?

It does.

So when administered orally, baclofen reaches its peak effect in about one hour, meaning the patient will feel that systemic dampening relatively quickly.

It has a half -life of three to five hours.

And a really significant clinical point here is that it's primarily eliminated unchanged.

Like what percentage?

About 70%.

Spray it in the urine.

So you must consider the patient's renal function before initiating therapy to prevent drug accumulation.

That makes total sense.

We know it is indicated for MS and spinal cord trauma, but the contraindications are just as important.

Absolutely.

Baclofen is not approved for managing spasticity related to cerebral palsy, stroke, Parkinson's disease, or Huntington Korea.

No, it's not.

And, strictly adhering to our golden rule, you should not be prescribing it for a localized acute muscle spasm.

Even though, I mean, we do occasionally see that happen off -label.

Unfortunately, yes we do.

And when you hand a patient a prescription for baclofen, the priority education centers on the consequences of that GABA -B agonism.

Because you are globally depressing the CNS.

Exactly.

Patients must be warned about profound drysiness, dizziness, weakness, and fatigue, especially during that initial dose titration phase.

You also have to aggressively counsel them to avoid alcohol and other CNS depressants.

The synergistic depression can really compromise their airway.

Oh wow.

Plus, GI and urinary smooth muscle tone can be affected, leading to nausea, constipation, and urinary retention in roughly 8 -10 % of patients.

So I want to pivot to a massive safety priority here.

Say a creation taking baclofen decides they feel better.

Or they lose their insurance and just can't get a refill.

The withdrawal risks are significant.

They are huge.

And they scale depending on the route of administration, right?

Yes.

Abrupt discontinuation is incredibly dangerous.

The central nervous system has down -regulated its own inhibitory processes in response to constant presence of the drug.

So if you abruptly withdraw oral baclofen, the brain is suddenly flooded with unchecked excitatory signals.

That manifests as visual hallucinations, paranoid ideation, and even seizures.

Wait, really?

Just from stopping the oral med?

Yes.

But the stakes are even higher with intralipical administration.

Right, when it's delivered directly into the subarachnoid space via an implanted pump.

Exactly.

Abrupt withdrawal there triggers a massive black box warning.

The physiological cascade is a literal medical emergency.

What does that look like?

Depriving the spinal cord of that concentrated inhibition causes high fever, altered mental status, and a violent exaggerated rebound of their spasticity.

That sounds terrifying.

It is.

The sustained titanic muscle contractions can become so severe that they actually trigger rhabdomyolysis.

The rapid necrosis of that muscle tissue dumps myoglobin into the bloodstream, which leads to acute renal failure, multiple organ system failure, and potentially death.

Wow.

So therapy must always be tapered slowly over like one to two weeks.

Always.

You can never just stop it.

Okay, so if centrally acting drugs like baclofen carry such profound risks of systemic depression and lethal withdrawal, the logical alternative would be to bypass the brain and spinal cord entirely, right?

You would think so, yes.

If we want to relax a muscle, why not act directly on the muscle?

That brings us to dantrolene.

The only direct acting muscle relaxant in Chapter 22.

Dantrolene's mechanism of action represents a completely different therapeutic strategy.

Instead of altering spinal cord transmission, it acts intracellularly right within the skeletal muscle itself.

By blocking the release of calcium from the sarcoplasmic reticulum.

Exactly.

And calcium is the essential trigger for the actin myosin cross -bridge cycle.

If you starve the myofibrils of calcium, the physical machinery of contraction just grinds So the spasticity decreases.

And fortunately, at therapeutic doses, it largely spares smooth and cardiac muscle.

Right.

It's utilized for spasticity from MS, cerebral palsy, spinal cord injuries.

And it's also the life -saving antidote for malignant hyperthermia.

But here's where it gets really interesting to me.

I struggle with the practical application of this.

Okay, how so?

Well, we are trying to improve the patient's quality of life, right?

But if we block calcium release to cure the spasticity, aren't we just inducing profound generalized weakness?

That is a great question.

Like, how is making a patient too weak to use their limbs a therapeutic victory?

You've hit on the central therapeutic dilemma of dantrolene.

That trade -off is exactly what clinicians struggle with.

Many patients with severe spasticity actually rely on that pathological rigidity.

Rely on it.

Yeah, to maintain your posture or to transfer from a bed to a wheelchair or just to stand upright.

If you eliminate the spasticity but replace it with flaccid weakness, you may drastically reduce their overall functional independence.

Oh, wow.

I didn't think about that.

Yeah.

So the guidelines actually require a trial period.

If you initiate dantrolene and there is no observable improvement in the patient's daily function within 45 days, the drug must be discontinued.

Right.

Because the weakness is not worth the risk if there's no functional gain.

Exactly.

And the risks extend far beyond weakness.

Dantrolene can cause drowsiness, diarrhea, and dysphagia.

And what about the IV formulation?

The IV formulation, which we use in malignant hyperthermia crises, is a severe vesicant.

Extravization will cause severe tissue necrosis, so meticulous 5E placement is absolutely mandatory.

But the ultimate monitoring parameter, the most severe systemic threat, is the liver, right?

It is.

Dantrolene carries a black box warning for fatal hepatotoxicity.

The incidence of dose -related symptomatic liver damage is approximately one in a thousand.

And deaths have occurred.

That's a really high incidence for something fatal.

It really is.

And the epidemiological data shows the risk is notably higher in women over the age of 35.

So managing that risk requires strict vigilance.

You must obtain baseline liver function tests before you write the prescription and conduct frequent periodic monitoring throughout therapy.

Yes.

You are always aiming for the lowest effective dose for the shortest duration possible.

And if those LFTs start trending upward, or if the patient reports jaundice, abdominal pain, or unexplained malaise?

You withdraw the drug immediately.

No questions asked.

Okay, let's transition away from permanent CNS lesions and focus on acute musculoskeletal injuries.

The therapeutic goal here shifts from managing chronic neurological spasticity to relieving localized pain and spasm.

Right, the weekend warrior we talked about.

Exactly.

We generally start with physical measures, NSAIDs, and then centrally acting muscle relaxants.

The prototype for localized muscle spasm is cyclobenzoprene.

Like baclofen, it operates in the central nervous system, but its primary site of activity is the brain stem rather than the spinal cord.

It reduces tonic motor activity, making it highly efficacious.

It's the typical first -choice treatment for acute localized spasm.

The pharmacokinetics of cyclobenzoprene, which are detailed in table 22 .2, really demand careful prescribing, particularly the extended release capsule.

Oh, definitely.

An immediate release dose peaks in about four hours.

The ER capsule normally have a half -life of eight to 37 hours, but cyclobenzoprene relies heavily on hepatic CYP pathways for clearance.

So if you prescribe this to a patient with hepatic impairment,

that half -life can skyrocket up to 188 hours.

A half -life of over a week for a single dose.

That means the drug will dangerously accumulate in a hepatically impaired patient.

You will see a massive amplification of its side effect profile.

Which is already significant due to its chemical architecture.

I love this chemical secret.

Cyclobenzoprene has a chemical structure that is nearly identical to tricyclic antidepressants.

Plus the TCAs.

That structural homology isn't just trivia, you know.

It completely defines the adverse effect profile.

Because it mimics a TCA, it induces significant muscarinic blockade.

The anticholinergic burden is substantial.

Your patient will likely experience dry mouth, blurred vision, photophobia, urinary retention, and constipation.

Nobody wants that.

No.

Furthermore, that tricyclic structure introduces cardiovascular risks.

You really have to monitor for cardiac rhythm disturbances, including sinus tachycardia and significant conduction delays.

And that structural similarity also triggers a massive safety alert regarding drug interactions, right?

It does.

Mixing cyclobenzoprene with monoamine oxidase inhibitors is strictly contraindicated.

Box 22 .1 details this.

If a patient is transitioning off an MAOI, a minimum of 14 days must elapse before you can safely introduce cyclobenzoprene.

Yes.

The washout period is critical.

If you administer them concurrently or fail to observe that washout period, you risk precipitating serotonin syndrome, which can be fatal.

And this can also happen if you combine cyclobenzoprene with SSRIs or SNRIs.

It manifests across three domains, right?

Autonomically, you'll see hypothermia, dipheresis, and severe tachycardia.

Right.

And neuromuscularly, the overstimulation causes tremors, hyperreflexia, muscle twitching, and clonus.

And then in the CNS, the patient will present with extreme agitation, confusion, and hallucinations.

You really must audit the patient's medication list for any serotoninergic drugs before prescribing.

It's non -negotiable.

Okay.

So, we have a clear understanding of our prototypes,

but Chapter 22 provides a long roster of other centrally acting drugs for localized spasm.

Carisaprodol, methocarbamol, metaxalone, clozoxazone.

There are quite a few.

As prescribers, we need to know exactly how these agents are stopping a localized muscle from spasming.

What specific neural pathway are we interrupting?

Well, here is a sobering clinical reality.

For most of these non -prototype drugs, the specific mechanism of action remains entirely unknown.

Wait, seriously.

We write millions of prescriptions for these muscle relaxants, and the actual mechanism is just a huge question mark.

It is.

I mean, in laboratory settings, massive toxic doses can depress spinal motor reflexes in animals, but at the therapeutic doses, we actually use in human patients.

The clinical consensus is that the relief of spasm is primarily secondary to their heavy sedative properties.

They are not seeking out a highly specific motor end play or spinal pathway.

They are just globally sedating the central nervous system.

Exactly.

A deeply sedated patient simply doesn't experience as much muscle spasm.

That is wild.

Though, there are two notable exceptions in this class, right?

Deaspam, which enhances the inhibitory effects of GABA,

and tizanidine, which acts as an antagonist at presynaptic alpha -2 receptors.

Right.

Those two have defined mechanisms.

But for the rest, you are essentially relying on generalized CNS depression.

Which is why understanding the specific quirks of each medication from tables 22 .1 and 22 .2 is so critical.

You are basically choosing between sedatives based largely on their individual risk profiles and side effects.

Okay, let's rapid fire analyze those specific profiles.

Starting with methocarbamol.

Methocarbamol's unique feature is that its metabolites can turn the patient's urine brown, black, or even dark green.

Oh wow.

Physiologically harmless though, right?

Completely harmless.

But clinically, if you fail to provide that patient education upfront, the patient will naturally assume they are experiencing rhabdomyolysis or severe hematuria.

Right.

They'll panic.

And chlorzoxazone also alters urine color orange to purple red, but it carries a far more sinister risk.

Yes.

Chlorzoxazone carries a risk of fatal hepatic necrosis.

Because we have an entire roster of safer, equally effective alternatives, the clinical consensus is that the risks of chlorzoxazone often outweigh its benefits.

So it's absolutely contraindicated in patients with any underlying liver disease.

Definitely.

What about tizanidine?

We know it's an alpha -2 agonist.

Because its mechanism mimics clonidine, it decreases sympathetic outflow.

Consequently, it causes significant dry mouth and marked hypotension.

And hallucinations, right?

Yes.

It carries a unique risk for visual hallucinations and psychotic symptoms.

And from an interaction standpoint, it is absolutely contraindicated with the antibiotic ciprofloxacin, which is a strong CYP1A2 inhibitor.

Because concomitant use will halt tizanidine's metabolism.

Exactly.

Leading to severe hypotensive toxicity.

And finally, curiciprodol and diazepam.

Both are schedule 4 controlled substances.

Chronic high -dose therapy leads to physical dependence.

And abrupt withdrawal can trigger a life -threatening abstinence syndrome.

And curiciprodol has that highly specific contraindication.

Right.

It must never be prescribed to patients with a history of intermittent porphyria, as it can precipitate an acute attack.

Okay.

So, a drug's SAE -C profile is entirely dependent on the physiological state of the patient taking it.

Clinical decision -making requires us to apply these pharmacological realities across the lifespan.

If we connect this to the bigger picture, how do these work in special populations?

Well, pediatric prescribing is heavily restricted in this class.

The guidelines explicitly state that chlorzoxazone, orphanadrine, and tizanidine are not approved for use in children.

The safety and efficacy simply haven't been established.

And in the context of pregnancy.

Cyclobenzaprine is considered relatively safe.

But diazepam is a known teratogen.

Exposure and utero is associated with low birth weights, prematurity, and severe respiratory depression at birth.

We also see neonatal withdrawal syndrome with both benzodiazepines like diazepam and with baclofen.

Yes, we do.

As a general rule, breastfeeding is not recommended across this entire class due to the risk of profound sedation and adverse effects in the infant.

The most critical population to scrutinize, though, is older adults.

I know almost the entire roster of centrally acting drugs.

Cariceprotal, Chlorzoxazone, Cyclobenzaprine, Metaxalone, Methacarbamol, and Orphanadrine.

They are explicitly listed on the BEERS criteria as potentially inappropriate for older adults.

They are.

And the physiological reasoning behind their inclusion on the BEERS criteria is exactly what we've been discussing today.

The anticholinergic burden.

First and foremost, yes.

The anticholinergic burden from drugs like Cyclobenzaprine can easily tip an older adult with decreased cognitive reserve into acute delirium.

And second, the heavy, generalized sedation creates a severe fall risk, which can lead to catastrophic fractures.

Exactly.

And third, the age -related decline in hepatic and renal function means these drugs take far longer to clear.

Long -acting drugs, particularly diazepam, will accumulate in their system.

Leading to profound, prolonged cognitive impairment and respiratory depression.

Exactly.

So synthesizing this chapter into a patient -centered framework requires strict vigilance.

Before prescribing, you must assess baseline liver and renal function.

You must monitor LFTs periodically, particularly with Dantrolene, Tizanidine, and Metaxalone.

You must initiate fall precautions for every patient due to the inherent CNS depression.

And you must exhaustively educate the patient to never abruptly stop therapy.

To avoid those life -threatening withdrawal cascades.

The ultimate irony of Chapter 22 is that to treat physical, mechanical muscle tension, we are almost entirely reliant on altering the central nervous system.

We are essentially sedating the brain to soothe the bicep.

It's a very blunt instrument.

It really is.

The next time you write a prescription for a muscle relaxant, you really have to ask yourself, are you actually relaxing the muscle?

Or are you just turning down the patient's neurological volume?

And is that temporary relief worth the systemic cost?

It forces you to evaluate the risk -to -benefit ratio with absolute precision.

You are trading localized pain for global neurological depression.

Well said.

The Deep Dive is brought to you by the Last Minute Lecture Team, so on their behalf, thank you for studying with us.

You've got this.